Coronavirus

https://childrenshealthdefense.org/d...8-345d40947a6c


03/04/22

FDA Releases 10,000 More Pfizer Vaccine Documents. What Will They Reveal?

The U.S. Food and Drug Administration on Tuesday released a 10,000-page cache of documents pertaining to the Emergency Use Authorization of Pfizer’s COVID vaccine. An initial review shows the documents contain details about animal studies, adverse events experienced by trial participants, the makeup of Pfizer’s internal review committee … and more.

By
Michael Nevradakis, Ph.D.

https://childrenshealthdefense.org/w...re-800x417.jpg

The U.S. Food and Drug Administration on Tuesday released a 10,000-page cache of documents pertaining to the Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID vaccine.

The documents provide more insights into the FDA’s process for approving the vaccine, and may also shed more light on the safety and efficacy of the vaccines and the number and nature of adverse effects that were observed during the clinical trials and the first months after the EUA was issued.

The documents were made public as part of a court-ordered release schedule stemming from an expedited Freedom of Information Act (FOIA) request by Public Health and Medical Professionals for Transparency (PHMPT).

PHMPT, a group of medical and public health professionals and scientists from Harvard, Yale, UCLA and other institutions, submitted the request in August 2021.

The FOIA request asked for the approximately 400,000 pages of documents pertaining to the approval of the Pfizer COVID vaccine to be made public, including safety and effectiveness data, adverse reaction reports and a list of the vaccine’s active and inactive ingredients.

When the FDA ignored the request, PHMPT sued the agency in September 2021, taking the case to the U.S. District Court for the Northern District of Texas. On Feb. 2, federal judge Mark Pittman issued an order requiring the FDA to release redacted versions of the documents in question according to the following disclosure schedule:

10,000 pages apiece, due on or before March 1 and April 1, 2022.
80,000 pages apiece, to be produced on or before May 2, June 1 and July 1, 2022.
70,000 pages to be produced on or before Aug. 1, 2022.
55,000 pages per month, on or before the first business day of each month thereafter, until the release of the documents has been completed.

The cache of documents made public on March 1, available on PHMPT’s website, represents the first release of such documents following the issuance of Pittman’s order in February.

However, the FDA released smaller sets of documents in November and December 2021 and January 2022, while the legal case was ongoing.

What do the documents reveal?

The first batch of documents, produced in November 2021 and totaling a mere 500 pages, revealed safety concerns and the fact that more than 1,200 vaccine-related deaths occurred within the first 90 days following the release of the Pfizer-BioNTech COVID vaccine.

The documents also revealed a nine-page list of adverse events observed during that same period. The list recently was circulated widely on social media and wrongly attributed to the set of documents released March 1.

This may be because the March 1 document release garnered widespread attention among those following the issue, likely delivering traffic to PHMPT’s website, which catalogs all of the documents that have been released thus far.

Major media outlets, however, have not covered the latest release of documents and, as of this writing, there has been only limited coverage by smaller media outlets. That may be due, at least in part, to the vast volume of information and data to sort through.

Endpoints News, a publication focusing on the pharmaceutical industry, published a dismissive article regarding the release of the latest cache of documents.

The publication’s editor, Zachary Brennan, reported the documents contain mundane information that is “typical for any drug or vaccine application” and that “will give readers a good overall sense of the required documentation necessary to apply for a drug or vaccine approval at the FDA.”

Such information includes, according to Brennan, “more than 100 pages worth of anonymous safety-related tables of data” and “unidentified participants’ gender, age and BMI.”

Other documentation pertains to “the standard, nearly $2.9 million user fee payment to FDA from Pfizer” and to “the confidential nonclinical overview for the vaccine,” Brennan said.

Brennan noted some documents included in the cache, such as the fast track designation letter and Pfizer’s request for a waiver from adding a suffix to the vaccine’s name, are “not typically released” to the public.

However, aside from this relatively mundane information — whether typically released to the public or not — the latest batch of documents may contain additional revelatory information.

An initial review by The Defender of the information included in this vast set of newly released documents includes:

Details regarding animal studies that were conducted, and their findings.
Documents that appear to pertain to specific types of adverse reactions experienced by trial participants, and to COVID-19 infections in trial participants post-vaccination.
Information about the study protocol, as well as amendments that were made to this protocol.
Information about Pfizer’s internal review committee for the COVID vaccine.
The original Pfizer-BioNTech application to market the COVID vaccine, submitted to the U.S. Department of Health and Human Services (HHS).

The sheer volume of information that must be analyzed and processed necessitates careful examination, which will be performed by the editorial staff of The Defender, with further information and any significant revelations to be published in the coming days.

A circuitous legal process and a victory for transparency

The FDA had previously argued it didn’t have enough staff to review, redact and release hundreds of thousands of pages of documents, claiming it could process only 500 pages per month.

This would have meant the cache of documents would not be fully released to the public for approximately 75 years.

In his Jan. 6 order, Pittmann rejected the FDA’s claim and instead required the agency to release 12,000 pages of documents by Jan. 31 and an additional 55,000 pages per month thereafter.

This decision was then amended by Pittman’s subsequent Feb. 2 order, truncating the release schedule to a matter of months instead of decades.

The Feb. 2 order also granted the FDA the ability to “bank” excess pages as part of this release schedule — meaning that if the agency exceeds its monthly quota in any given month it can apply those extra pages to a subsequent month.

Previously, Pfizer responded to the Jan. 6 order by filing a memorandum with the court requesting to intervene in the case to assist the FDA with the documents’ release, specifically for the “limited purpose of ensuring that information exempt from disclosure under FOIA is adequately protected as FDA complies with this Court’s order.”

Pfizer claimed to support the disclosure of the documents, but asked to intervene in the case to ensure that information legally exempt from disclosure will not be “disclosed inappropriately.”

Pittman rejected Pfizer’s bid in his Feb. 2 order.

In a related matter, Judge Michael Truncale of the U.S. District Court for the Eastern District of Texas on Feb. 10 unsealed 400 pages of documents pertaining to a lawsuit filed by a whistleblower, Brook Jackson.

Jackson formerly worked for Ventavia, a contractor hired by Pfizer to conduct Phase 3 clinical trials of the Pfizer-BioNTech COVID vaccine.

Jackson’s lawsuit alleges multiple improprieties in the clinical trial process during the time that she was employed with Ventavia. The FDA declined to intervene in this case.

Some of the documents pertaining to the approval of the Pfizer-BioNTech COVID vaccine that were released on March 1 appear to directly relate to the clinical trials conducted by Ventavia, and thus may shed light on Jackson’s allegations.

The views and opinions expressed in this article are those of the authors and do not necessarily reflect the views of Children's Health Defense.

https://www.youtube.com/watch?v=TtYI5zdmDlQ

https://www.youtube.com/watch?v=TtYI5zdmDlQ

Clinton Cash Machine in Bed w/ Russians, Fauci-China Coverup, Judicial Watch Fights Court Corruption
7,513 views
Premiered 3 hours ago

50:51 video runtime

17:10 to 38:18 The deep and wide CORRUPTION attendant to the PLANdemic.


Fauci Agency Cover-Up Exposed

China Failed to Provide Key COVID Info, Fauci Agency Records Show
Judicial Watch Sues Court Officials for Firing Magistrate After She Made Public Comment about Wrongdoing Tied to Murder
The Clintons’ Russia-Ukraine Grift


__________________________

https://www.judicialwatch.org/fauci-...eekly%20update

Fauci Agency Cover-Up Exposed
March 04, 2022 | Judicial Watch


China Failed to Provide Key COVID Info, Fauci Agency Records Show

China has been accused of obstructing investigations into the origins of the COVID virus, and we can now add another piece to that puzzle.

We received 90 pages of records from the Department of Health and Human Services (HHS) that show the State Department and Dr. Anthony Fauci’s agency, the U.S. National Institute of Allergy and Infectious Diseases (NIAID), knew immediately in January 2020 that China was withholding COVID data, and this was hindering risk assessment and response by public health officials.

The records also show that, nearly two years before the coronavirus outbreak, the U.S. National Institutes of Health (NIH) sent “experts” from the NIH-supported P4 lab at the University of Texas Medical Branch to train Wuhan Institute of Virology lab technicians in lab management and maintenance due to the Wuhan lab’s shortage of trained staff. The same April 2018 cable noted that an official from EcoHealth Alliance “plans to visit Wuhan to meet with Shi [Zhengli].”

We obtained the records through our Freedom of Information Act (FOIA) lawsuit for records of communications, contracts and agreements with the Wuhan Institute of Virology (Judicial Watch, Inc. v. U.S. Department of Health and Human Services (No. 1:21-cv-00696)). The lawsuit specifically sought records about NIH grants that benefitted the Wuhan Institute of Virology.

The novel coronavirus outbreak began in Wuhan, China, in December 2019.

After the outbreak, on January 8, 2020, Dr. Ping Chen, who had been NIAID’s top official in China, emails senior NIAID colleagues Gray Handley, Erik Stemmy, Gayle Bernabe, and Barney Graham with the subject line “PRC Response to Pneumonia Cases Shows Increased Transparency Over Past Outbreaks, but Gaps in Epidemiological Data Remain.” Chen writes:

hi, here is the cable from US Embassy Beijing reporting on the pneumonia outbreak in Wuhan, China. It has ruled out SARS, MERS, and flu. [Redacted] confirmed it is viral infection. [Redacted] The cable contains SBU information. So please don’t distribute it widely.

The summary of the cable states:

While PRC officials have released timely and open general information about the outbreak, a lack of epidemiologic data – including an ‘epi curve’ (a summary of dates of onset of illness), characteristics of infected individuals, and other basic epidemiologic information – hinders better risk assessment and response by public health officials. Authorities have also not released information on how they are defining a “case.” Given these gaps in detailed information to-date, and lack of a final confirmed pathogen, the risk to the United States and global health is difficult to assess at this time.

***

As of January 7, the Wuhan Health Commission has reported 59 local cases of pneumonia with unknown cause. (Note: Wuhan, a city of approximately 11 million people, is the capital of Central China’s Hubei Province. End note.) According to the Health Commission, some patients are vendors who work in the Huanan Seafood Market, which also sells live exotic animals, including beaver, snakes, porcupines, and deer.

***

Health officials state there has been no confirmed human-to-human transmission of the disease, and no cases among health workers. Laboratory investigations have ruled out influenza, avian influenza, SARS, MERS, and other common respiratory pathogens, and are awaiting final pathogen results.

***

PRC [People’s Republic of China] officials on December 31, 2019 alerted WHO to the pneumonia outbreak. WHO contacts told Embassy officials that PRC health departments continue to provide information about the outbreak in accordance with WHO’s International Health Regulations (IRR). While China has been forthcoming with standard information, WHO contacts note they have not received more detailed and potentially useful information, such as “epi curves” or other epidemiological data. The flow of official PRC information on this outbreak is limited to that coming from the Wuhan Health Commission and National Health Commission.

On January 30, 2020, Chen forwards to senior NIAID colleagues Gray Handley, Gayle Bernabe, Joyelle Dominique, William Rosa, Tami Lu and Hilary Marsten a cable issued by the U.S. Embassy in Beijing, which provides a detailed situation report on Chinese government responses to the then-fast spreading SARS-CoV-2 virus from across the country. The cable discusses Chinese virus mitigation measures, infection case numbers, travel restrictions, and quarantine measures then taking place in Beijing, Chengdu, Guangzhou, Shanghai, and Shenyang.

In a section discussing “Media/Social Media” reporting on the virus in China, the cable discusses a Global Times article about the “detention” in early January 2020 of eight Chinese residents for spreading “rumors” about the outbreak of the virus:

[An] article in Global Times praised Wuhan residents for “whistle-blowing” on virus outbreak. A top epidemiologist at the Chinese Center for Disease Control and Prevention (CCDC) on Wednesday commended eight residents, who were detained in early January for spreading “rumors” about the outbreak of the novel coronavirus. Zeng Guang, Chief epidemiologist at the CCDC, said those eight residents should be highly regarded as they turned out to be correct about the viral outbreak, even though the information they spread “lacked scientific evidence.” Zeng’s comment followed an article from the Supreme People’s Court of China (SPC) on Tuesday, in which the top court said that the eight Wuhan residents should be “tolerated” and their act of spreading the information, if taken seriously, would have done much good to the public.

On April 15, 2020, an official whose name is redacted sends an email to colleagues labeled “WIV [Wuhan Institute of Virology] Cables,” and writes, “As I am sure you are quite aware at this point the cables ESTH [State Department’s Environment, Science, Technology and Health Section] wrote on the WIV lab and the concerns we had about the findings of the papers on bat coronavirus research have become big news lately.”

An official forwards an email exchange from April 12, 2018, labeled “For your review – Cable on Wuhan Institute of Virology visit.” That email attached a cable titled “China Virus Institute Welcomes More U.S. Cooperation on Global Health Security.” The partially redacted summary of the cable begins:

China’s Wuhan Institute of Virology, a global leader of virus research, is a key partner for the United States in protecting global health security. Its role as operator of the just-launched ‘P4’ lab – the first such lab in China – opens up even more opportunities for expert exchange, especially in light of the lab’s shortage of trained staff.

The cable also mentions that there is also a “U.S. Centers for Disease Control (CDC)-supported [P4 lab] facility in Pune, India,” and that China “plans to stand up a second P4 lab in Harbin.” Harbin is the capital of Heilongjiang province in northeastern China.

The cable notes that Chinese officials, “described the [Wuhan] lab as a ’regional node’ in the global biosafety system and said it would play an emergency response role in an epidemic or pandemic.” It continues, “[E]xperts from the NIH-supported P4 lab at the University of Texas Medical Branch have trained Wuhan lab technicians in lab management and maintenance, institute officials said.” It went on, “NIH was a major funder, along with China’s National Science Foundation, of SARS research by the Wuhan Institute of Virology’s [redacted].” Finally, the cable notes, “[Redacted] with the EcoHealth Alliance (a New York City-based NGO that is working with the University of California Davis to manage the [redacted], plans to visit Wuhan to meet with Shi [Zhengli].”

Well prior to the outbreak, on October 2, 2017, NIAID Associate Director Gray Handley forwards to colleagues a State Department cable titled “China’s Interest in the Global Virome Project Presents an Opportunity for Global Health Cooperation,” which another official notes “seems relevant to biobanking, IP [likely Intellectual Property], pandemic flu, and a bunch of other issue areas.”

The summary of the cable begins:

The proposed Global Virome Project (GVP), an international non-governmental organization built on a decade-long prototype initiated by the U.S. Agency for International Development (USAID), seeks to address vulnerability from emerging diseases by creating a global database of viruses of animal origin and identifying those pathogens with greatest potential to jump to humans through sequencing their genomes, understanding the ecology involved in transmission, and assessing risk to humans. This knowledge could then be used to devise treatments and countermeasures.

The cable states: “U.S-China collaboration on the Global Virome Project in an opportunity to lead innovation in science, collaborate with China, and potentially contribute to scientific breakthroughs.”

The records include a February 23, 2018, email between the U.S. Embassy in Beijing and NIH headquarters, in which NIH officials were monitoring “China Health News from Chinese Media through 02/23/2018:”

Research at the Wuhan Institute of Virology into how bats “harbor highly pathogenic viruses like Ebola, Marburg and SARS coronavirus but do not show clinical signs of disease.”
New Chinese discoveries that certain Traditional Chinese Medicines (TCM) could be used to combat bacterial and viral infections which Western medicines could not address due to growing antimicrobial resistance (AMR) to the Western drugs. They note, “Previous experiences showed than TCM remedies can be used as a substitute for Western antibiotics in the presence of some viral diseases, or lower the viral load” and that “further largescale clinical trials are needed before TCM antibiotics can be embraced and promoted globally.”
A new nano-technology based flu vaccine the Chinese were developing at the Wuhan Institute of Virology.
Chinese advances in “Human Gene Therapy”, in which “China is helping to advance gene and cell therapy and genome editing research by creating novel viral and nonviral vectors for gene delivery and innovative applications of CRISPR technology in a broad range of disease areas.”

These documents show that Fauci’s agency has been hiding information on China’s failure to provide essential data on COVID-19. The slow-rolling and stonewalling by Fauci’s agency on China, gain of function, and its COVID response generally is pure obstruction.

We have been deeply involved in investigations into the origins of COVID-19 and have brought a number of facts to light.

In July 2021, Judicial Watch obtained records from NIAID officials in connection with the Wuhan Institute of Virology revealing significant collaborations and funding that began in 2014. The records revealed that NIAID gave nine China-related grants to EcoHealth Alliance to research coronavirus emergence in bats and was the NIH’s top issuer of grants to the Wuhan lab itself.

In June 2021, Judicial Watch obtained documents from HHS revealing that from 2014 to 2019, $826,277 was given to the Wuhan Institute of Virology for bat coronavirus research by the National Institute of Allergy and Infectious Diseases (NIAID), which is headed by Dr. Anthony Fauci.

In March 2021, Judicial Watch publicly released emails and other records of Dr. Anthony Fauci and Dr. H. Clifford Lane from HHS showing that National Institutes of Health (NIH) officials tailored confidentiality forms to China’s terms and that the World Health Organization (WHO) conducted an unreleased, “strictly confidential” COVID-19 epidemiological analysis in January 2020.

In October 2020, we uncovered emails showing a WHO entity pushing for a press release, approved by Dr. Fauci, “especially” supporting China’s COVID-19 response.

It’s clear that our own medical bureaucrats, like the Chinese, have been less than forthcoming about this whole troubling matter.

https://trib247.com/articles/adverse...ign=Newsletter

Part 1 of ? Parts to be continued

Adverse effects? Pfizer’s Covid vaccine has had a few

by: WorldTribune.com 03/04/2022 Source: WorldTribune.com

https://structurecms-production-psyc...jpg?1646373530

Via the Internet Wayback Machine:

A document submitted by Pfizer-BioNTech as part of its Biological License Application (BLA) for the Covid vaccine to the FDA, entitled “5.3.6 Cumulative analysis of post-authorization adverse event reports of pf-07302048 (bnt162b2) received through 28-feb-2021”, looked at adverse event reports from Dec. 1, 2020, through Feb. 28, 2021 from 63 countries. Most reports came from the United States and the United Kingdom.

The BLA is a request for permission to introduce or distribute a new biologic product across states. The FDA reviews the information in the BLA “to make sure the vaccine is safe and effective and meets the FDA’s standards for approval.”

The data was collected from surveillance systems like the U.S. government’s Vaccine Adverse Event Reporting System (VAERS), and the UK’s Yellow Card Scheme as well as “cases published in the medical literature, cases from Pfizer-sponsored marketing programs, non-interventional studies, and cases of serious AEs reported from clinical studies regardless of causality assessment,” the document states.

The adverse events included:

1p36 deletion syndrome;
2-Hydroxyglutaric aciduria;
5'nucleotidase increased;
Acoustic neuritis;
Acquired C1 inhibitor deficiency;
Acquired epidermolysis bullosa;
Acquired epileptic aphasia;
Acute cutaneous lupus erythematosus;
Acute disseminated encephalomyelitis;
Acute encephalitis with refractory, repetitive partial seizures;
Acute febrile neutrophilic dermatosis;
Acute flaccid myelitis;
Acute haemorrhagic leukoencephalitis;
Acute haemorrhagic oedema of infancy;
Acute kidney injury;
Acute macular outer retinopathy;
Acute motor axonal neuropathy;
Acute motor-sensory axonal neuropathy;
Acute myocardial infarction;
Acute respiratory distress syndrome;
Acute respiratory failure;
Addison's disease;
Administration site thrombosis;
Administration site vasculitis;
Adrenal thrombosis;
Adverse event following immunisation;
Ageusia;
Agranulocytosis;
Air embolism;
Alanine aminotransferase abnormal;
Alanine aminotransferase increased;
Alcoholic seizure;
Allergic bronchopulmonary mycosis;
Allergic oedema;
Alloimmune hepatitis;
Alopecia areata;
Alpers disease;
Alveolar proteinosis;
Ammonia abnormal;
Ammonia increased;
Amniotic cavity infection;
Amygdalohippocampectomy;
Amyloid arthropathy;
Amyloidosis;
Amyloidosis senile;
Anaphylactic reaction;
Anaphylactic shock;
Anaphylactic transfusion reaction;
Anaphylactoid reaction;
Anaphylactoid shock;
Anaphylactoid syndrome of pregnancy;
Angioedema;
Angiopathic neuropathy;
Ankylosing spondylitis;
Anosmia;
Antiacetylcholine receptor antibody positive;
Anti-actin antibody positive;
Anti-aquaporin-4 antibody positive;
Anti-basal ganglia antibody positive;
Anti-cyclic citrullinated peptide antibody positive;
Anti-epithelial antibody positive;
Anti-erythrocyte antibody positive;
Anti-exosome complex antibody positive;
Anti-GAD antibody negative;
Anti-GAD antibody positive;
Anti-ganglioside antibody positive;
Antigliadin antibody positive;
Anti-glomerular basement membrane antibody positive;
Anti-glomerular basement membrane disease;
Anti-glycyl-tRNA synthetase antibody positive;
Anti-HLA antibody test positive;
Anti-IA2 antibody positive;
Anti-insulin antibody increased;
Anti-insulin antibody positive;
Anti-insulin receptor antibody increased;
Anti-insulin receptor antibody positive;
Anti-interferon antibody negative;
Anti-interferon antibody positive;
Anti-islet cell antibody positive;
Antimitochondrial antibody positive;
Anti-muscle specific kinase antibody positive;
Anti-myelin-associated glycoprotein antibodies positive;
Anti-myelin-associated glycoprotein associated polyneuropathy;
Antimyocardial antibody positive;
Anti-neuronal antibody positive;
Antineutrophil cytoplasmic antibody increased;
Antineutrophil cytoplasmic antibody positive;
Anti-neutrophil cytoplasmic antibody positive vasculitis;
Anti-NMDA antibody positive;
Antinuclear antibody increased;
Antinuclear antibody positive;
Antiphospholipid antibodies positive;
Antiphospholipid syndrome;
Anti-platelet antibody positive;
Anti-prothrombin antibody positive;
Antiribosomal P antibody positive;
Anti-RNA polymerase III antibodypositive;
Anti-saccharomyces cerevisiae antibody test positive;
Anti-sperm antibody positive;
Anti-SRP antibody positive;
Antisynthetase syndrome;
Anti-thyroid antibody positive;
Anti-transglutaminase antibody increased;
Anti-VGCC antibody positive;
Anti-VGKC antibody positive;
Anti-vimentin antibody positive;
Antiviral prophylaxis;
Antiviral treatment;
Anti-zinc transporter 8 antibody positive;
Aortic embolus;
Aortic thrombosis;
Aortitis;
Aplasia pure red cell;
Aplastic anaemia;
Application site thrombosis;
Application site vasculitis;
Arrhythmia;
Arterial bypass occlusion;
Arterial bypass thrombosis;
Arterial thrombosis;
Arteriovenous fistula thrombosis;
Arteriovenous graft site stenosis;
Arteriovenous graft thrombosis;
Arteritis; Arteritis coronary;
Arthralgia;
Arthritis;
Arthritis enteropathic;
Ascites;
Aseptic cavernous sinus thrombosis;
Aspartate aminotransferase abnormal;
Aspartate aminotransferase increased;
Aspartate-glutamate-transporter deficiency;
AST to platelet ratio index increased;
AST/ALT ratio abnormal;
Asthma;
Asymptomatic COVID-19;
Ataxia;
Atheroembolism;
Atonic seizures;
Atrial thrombosis;
Atrophic thyroiditis;
Atypical benign partial epilepsy;
Atypical pneumonia;
Aura;
Autoantibody positive;
Autoimmune anaemia;
Autoimmune aplastic anaemia;
Autoimmune arthritis;
Autoimmune blistering disease;
Autoimmune cholangitis;
Autoimmune colitis;
Autoimmune demyelinating disease;
Autoimmune dermatitis;
Autoimmune disorder;
Autoimmune encephalopathy;
Autoimmune endocrine disorder;
Autoimmune enteropathy;
Autoimmune eye disorder;
Autoimmune haemolytic anaemia;
Autoimmune heparin-induced thrombocytopenia;
Autoimmune hepatitis; Autoimmune hyperlipidaemia;
Autoimmune hypothyroidism;
Autoimmune inner ear disease;
Autoimmune lung disease;
Autoimmune lymphoproliferative syndrome;
Autoimmune myocarditis;
Autoimmune myositis;
Autoimmune nephritis;
Autoimmune neuropathy;
Autoimmune neutropenia;
Autoimmune pancreatitis;
Autoimmune pancytopenia;
Autoimmune pericarditis;
Autoimmune retinopathy;
Autoimmune thyroid disorder;
Autoimmune thyroiditis;
Autoimmune uveitis;
Autoinflammation with infantile enterocolitis;
Autoinflammatory disease;
Automatism epileptic;
Autonomic nervous system imbalance;
Autonomic seizure;
Axial spondyloarthritis;
Axillary vein thrombosis;
Axonal and demyelinating polyneuropathy;
Axonal neuropathy;
Bacterascites;
Baltic myoclonic epilepsy;
Band sensation;
Basedow's disease;
Basilar artery thrombosis;
Basophilopenia;
B-cell aplasia;
Behcet's syndrome;
Benign ethnic neutropenia;
Benign familial neonatal convulsions;
Benign familial pemphigus;
Benign rolandic epilepsy;
Beta-2 glycoprotein antibody positive;
Bickerstaff's encephalitis;
Bile output abnormal;
Bile output decreased;
Biliary ascites;
Bilirubin conjugated abnormal;
Bilirubin conjugated increased;
Bilirubin urine present;
Biopsy liver abnormal;
Biotinidase deficiency;
Birdshot chorioretinopathy;
Blood alkaline phosphatase abnormal;
Blood alkaline phosphatase increased;
Blood bilirubin abnormal;
Blood bilirubin increased;
Blood bilirubin unconjugatedincreased;
Blood cholinesterase abnormal;
Blood cholinesterase decreased;
Blood pressure decreased;
Blood pressure diastolic decreased;
Blood pressure systolic decreased;
Blue toe syndrome;
Brachiocephalic vein thrombosis;
Brain stem embolism;
Brain stem thrombosis;
Bromosulphthalein test abnormal;
Bronchial oedema;
Bronchitis;
Bronchitis mycoplasmal;
Bronchitis viral;
Bronchopulmonary aspergillosis allergic;
Bronchospasm;
Budd-Chiari syndrome;
Bulbar palsy;
Butterfly rash;
C1q nephropathy;
Caesarean section;
Calcium embolism;
Capillaritis;
Caplan's syndrome;
Cardiac amyloidosis;
Cardiac arrest;
Cardiac failure;
Cardiac failure acute;
Cardiac sarcoidosis;
Cardiac ventricular thrombosis;
Cardiogenic shock;
Cardiolipin antibody positive;
Cardiopulmonary failure;
Cardio-respiratory arrest;
Cardio-respiratory distress;
Cardiovascular insufficiency;
Carotid arterial embolus;
Carotid artery thrombosis;
Cataplexy;
Catheter site thrombosis;
Catheter site vasculitis;
Cavernous sinus thrombosis;
CDKL5 deficiency disorder;
CEC syndrome;
Cement embolism;
Central nervous system lupus;
Central nervous system vasculitis;
Cerebellar artery thrombosis;
Cerebellar embolism;
Cerebral amyloid angiopathy;
Cerebral arteritis;
Cerebral artery embolism;
Cerebral artery thrombosis;
Cerebral gas embolism;
Cerebral microembolism;
Cerebral septic infarct;
Cerebral thrombosis;
Cerebral venous sinus thrombosis;

Part 2 of ? Parts to be continued

Cerebral venous thrombosis;
Cerebrospinal thrombotic tamponade;
Cerebrovascular accident;
Change in seizure presentation;
Chest discomfort;
Child-Pugh-Turcotte score abnormal;
Child-Pugh-Turcotte score increased;
Chillblains;
Choking;
Choking sensation;
Cholangitis sclerosing;
Chronic autoimmune glomerulonephritis;
Chronic cutaneous lupus erythematosus;
Chronic fatigue syndrome;
Chronic gastritis;
Chronic inflammatory demyelinating polyradiculoneuropathy;
Chronic lymphocytic inflammation with pontine perivascular
enhancement responsive to steroids;
Chronic recurrent multifocal osteomyelitis;
Chronic respiratory failure;
Chronic spontaneous urticaria;
Circulatory collapse;
Circumoral oedema;
Circumoral swelling;
Clinically isolated syndrome;
Clonic convulsion;
Coeliac disease; Cogan's syndrome;
Cold agglutinins positive;
Cold type haemolytic anaemia;
Colitis; Colitis erosive;
Colitis herpes;
Colitis microscopic;
Colitis ulcerative;
Collagendisorder;
Collagen-vascular disease;
Complement factor abnormal;
Complement factor C1 decreased;
Complement factor C2 decreased;
Complement factor C3 decreased;
Complement factor C4 decreased;
Complement factor decreased;
Computerised tomogram liver abnormal;
Concentric sclerosis;
Congenital anomaly;
Congenital bilateral perisylvian syndrome;
Congenital herpes simplex infection;
Congenital myasthenic syndrome;
Congenital varicella infection;
Congestive hepatopathy;
Convulsion in childhood;
Convulsions local;
Convulsive threshold lowered;
Coombs positive haemolytic anaemia;
Coronary artery disease;
Coronary artery embolism;
Coronary artery thrombosis;
Coronary bypass thrombosis;
Coronavirus infection;
Coronavirus test;
Coronavirus test negative;
Coronavirus test positive;
Corpus callosotomy;
Cough;
Cough variant asthma;
COVID-19;
COVID-19 immunisation;
COVID-19 pneumonia;
COVID-19 prophylaxis;
COVID-19 treatment;
Cranial nerve disorder;
Cranial nerve palsies multiple;
Cranial nerve paralysis;
CREST syndrome;
Crohn's disease;
Cryofibrinogenaemia;
Cryoglobulinaemia;
CSF oligoclonal band present;
CSWS syndrome;
Cutaneous amyloidosis;
Cutaneous lupus erythematosus;
Cutaneous sarcoidosis;
Cutaneous vasculitis;
Cyanosis; Cyclic neutropenia;
Cystitis interstitial;
Cytokine release syndrome;
Cytokine storm;
De novo purine synthesis inhibitors associated acute inflammatory syndrome;
Death neonatal;
Deep vein thrombosis;
Deep vein thrombosis postoperative;
Deficiency of bile secretion;
Deja vu;
Demyelinating polyneuropathy;
Demyelination;
Dermatitis;
Dermatitis bullous;
Dermatitis herpetiformis;
Dermatomyositis;
Device embolisation;
Device related thrombosis;
Diabetes mellitus;
Diabetic ketoacidosis;
Diabetic mastopathy;
Dialysis amyloidosis;
Dialysis membrane
reaction;
Diastolic hypotension;
Diffuse vasculitis;
Digital pitting scar;
Disseminated intravascular coagulation;
Disseminated intravascular coagulation in newborn;
Disseminated neonatal herpes simplex;
Disseminated varicella;
Disseminated varicella zoster vaccine virus infection;
Disseminated varicella zoster virus infection;
DNA antibody positive;
Double cortex syndrome;
Double stranded DNA antibody positive;
Dreamy state;
Dressler's syndrome;
Drop attacks;
Drug withdrawal convulsions;
Dyspnoea;
Early infantile epileptic encephalopathy with burst-suppression; Eclampsia;
Eczema herpeticum;
Embolia cutis medicamentosa;
Embolic cerebellar infarction;
Embolic cerebral infarction;
Embolic pneumonia;
Embolic stroke;
Embolism;
Embolism arterial;
Embolism venous;
Encephalitis;
Encephalitis allergic;
Encephalitis autoimmune;
Encephalitis brain stem;
Encephalitis haemorrhagic;
Encephalitis periaxialis diffusa;
Encephalitis post immunisation;
Encephalomyelitis;
Encephalopathy;
Endocrine disorder;
Endocrine ophthalmopathy;
Endotracheal intubation;
Enteritis;
Enteritis leukopenic;
Enterobacter pneumonia;
Enterocolitis;
Enteropathic spondylitis;
Eosinopenia;
Eosinophilic fasciitis;
Eosinophilic granulomatosis with polyangiitis;
Eosinophilic oesophagitis;
Epidermolysis;
Epilepsy;
Epilepsy surgery;
Epilepsy with myoclonic-atonic seizures;
Epileptic aura;
Epileptic psychosis;
Erythema;
Erythema induratum;
Erythema multiforme;
Erythema nodosum;
Evans syndrome;
Exanthema subitum;
Expanded disability status scale score decreased;
Expanded disability status scale score increased;
Exposure to communicable disease;
Exposure to SARS-CoV-2;
Eye oedema;
Eye pruritus;
Eye swelling;
Eyelid oedema;
Face oedema;
Facial paralysis;
Facial paresis;
Faciobrachial dystonic seizure;
Fat embolism;
Febrile convulsion;
Febrile infection-related epilepsy syndrome;
Febrile neutropenia;
Felty's syndrome;
Femoral artery embolism;
Fibrillary glomerulonephritis;
Fibromyalgia;
Flushing;
Foaming at mouth;
Focal cortical resection;
Focal dyscognitive seizures;
Foetal distress syndrome;
Foetal placental thrombosis;
Foetor
hepaticus;
Foreign body embolism;
Frontal lobe epilepsy;
Fulminant type 1 diabetes mellitus;
Galactose elimination capacity test abnormal;
Galactose elimination capacity test decreased;
Gamma-glutamyltransferase abnormal;
Gamma-glutamyltransferase increased;
Gastritis herpes;
Gastrointestinal amyloidosis;
Gelastic seizure;
Generalised onset non-motor seizure;
Generalised tonic-clonic seizure;
Genital herpes;
Genital herpes simplex;
Genital herpes zoster;
Giant cell arteritis;
Glomerulonephritis;
Glomerulonephritis membranoproliferative;
Glomerulonephritis membranous;
Glomerulonephritis rapidly progressive;
Glossopharyngeal nerve paralysis;
Glucose transporter type 1 deficiency syndrome;
Glutamate dehydrogenase increased;
Glycocholic acid increased;
GM2 gangliosidosis;
Goodpasture's syndrome;
Graft thrombosis;
Granulocytopenia;
Granulocytopenia neonatal;
Granulomatosis with polyangiitis;
Granulomatous dermatitis;
Grey matter heterotopia;
Guanase increased;
Guillain-Barre syndrome;

Part 3 of 3 Parts

Haemolytic anaemia;
Haemophagocytic lymphohistiocytosis;
Haemorrhage;
Haemorrhagic ascites;
Haemorrhagic disorder;
Haemorrhagic pneumonia;
Haemorrhagic varicella syndrome;
Haemorrhagic vasculitis;
Hantavirus pulmonary infection;
Hashimoto's encephalopathy;
Hashitoxicosis;
Hemimegalencephaly;
Henoch-Schonlein purpura;

Henoch-Schonlein purpura nephritis;
Hepaplastin abnormal;
Hepaplastin decreased;
Heparin-induced thrombocytopenia;
Hepatic amyloidosis;
Hepatic artery embolism;
Hepatic artery flow decreased;
Hepatic artery thrombosis;
Hepatic enzyme abnormal;
Hepatic enzyme decreased;
Hepatic enzyme increased;
Hepatic fibrosis marker abnormal;
Hepatic fibrosis marker increased;
Hepatic function abnormal;
Hepatic hydrothorax;
Hepatic hypertrophy;
Hepatic hypoperfusion;
Hepatic lymphocytic infiltration;
Hepatic mass;
Hepatic pain;
Hepatic sequestration;
Hepatic vascular resistance increased;
Hepatic vascular thrombosis;
Hepatic vein embolism;
Hepatic vein thrombosis;
Hepatic venous pressure gradient abnormal;
Hepatic venous pressure gradient increased;
Hepatitis; Hepatobiliary scan abnormal;
Hepatomegaly;
Hepatosplenomegaly;
Hereditary angioedema with C1 esterase inhibitor deficiency;
Herpes dermatitis;
Herpes gestationis;
Herpes oesophagitis;
Herpes ophthalmic;
Herpes pharyngitis;
Herpes sepsis;
Herpes simplex;
Herpes simplex cervicitis;
Herpes simplex colitis;
Herpes simplex encephalitis;
Herpes simplex gastritis;
Herpes simplex hepatitis;
Herpes simplex meningitis;
Herpes simplex meningoencephalitis;
Herpes simplex meningomyelitis;
Herpes simplex necrotising retinopathy;
Herpes simplex oesophagitis;
Herpes simplex otitis externa;
Herpes simplex pharyngitis;
Herpes simplex pneumonia;
Herpes simplex reactivation;
Herpes simplex sepsis;
Herpes simplex viraemia;
Herpes simplex virus conjunctivitis neonatal;
Herpes simplex visceral;
Herpes virus infection;
Herpes zoster;
Herpes zoster cutaneous disseminated;
Herpes zoster infection neurological;
Herpes zoster meningitis;
Herpes zoster meningoencephalitis;
Herpes zoster meningomyelitis;
Herpes zoster meningoradiculitis;
Herpes zoster necrotizing retinopathy;
Herpes zoster oticus;
Herpes zoster pharyngitis;
Herpes zosterreactivation;
Herpetic radiculopathy;
Histone antibody positive;
Hoigne's syndrome;
Human herpesvirus 6 encephalitis;
Human herpesvirus 6 infection;
Human herpesvirus 6 infection reactivation;
Human herpesvirus 7 infection;
Human herpesvirus 8 infection;
Hyperammonaemia;
Hyperbilirubinaemia;
Hypercholia;
Hypergammaglobulinaemia benign monoclonal;
Hyperglycaemic seizure;
Hypersensitivity;
Hypersensitivity vasculitis;
Hyperthyroidism;
Hypertransaminasaemia;
Hyperventilation;
Hypoalbuminaemia;
Hypocalcaemic seizure;
Hypogammaglobulinaemia;
Hypoglossal nerve paralysis;
Hypoglossal nerve paresis;
Hypoglycaemic seizure;
Hyponatraemic seizure;
Hypotension;
Hypotensive crisis;
Hypothenar hammer syndrome;
Hypothyroidism;
Hypoxia;
Idiopathic CD4 lymphocytopenia;
Idiopathic generalised epilepsy;
Idiopathic interstitial pneumonia;
Idiopathic neutropenia;
Idiopathic pulmonary fibrosis;
IgA nephropathy;
IgM nephropathy;
IIIrd nerve paralysis;
IIIrd nerve paresis;
Iliac artery embolism;
Immune thrombocytopenia;
Immune-mediated adverse reaction;
Immune-mediated cholangitis;
Immune-mediated cholestasis;
Immune-mediated cytopenia;
Immune-mediated encephalitis;
Immune-mediatedencephalopathy;
Immune-mediated endocrinopathy;
Immune-mediated enterocolitis;
Immune-mediated gastritis;
Immune-mediated hepatic disorder;
Immune-mediated hepatitis;
Immune-mediated hyperthyroidism;
Immune-mediated hypothyroidism;
Immune-mediated myocarditis;
Immune-mediated myositis;
Immune-mediated nephritis;
Immune-mediated neuropathy;
Immune-mediated pancreatitis;
Immune-mediated pneumonitis;
Immune-mediated renal disorder;
Immune-mediated thyroiditis;
Immune-mediated uveitis;
Immunoglobulin G4 related disease;
Immunoglobulins abnormal;
Implant site thrombosis;
Inclusion body myositis;
Infantile genetic agranulocytosis;
Infantile spasms;
Infected vasculitis;
Infective thrombosis;
Inflammation;
Inflammatory bowel disease;
Infusion site thrombosis;
Infusion site vasculitis;
Injection site thrombosis;
Injection site urticaria;
Injection site vasculitis;
Instillation site thrombosis;
Insulin autoimmune syndrome;
Interstitial granulomatous dermatitis;
Interstitial lung disease;
Intracardiac mass;
Intracardiac thrombus;
Intracranial pressure increased;
Intrapericardial thrombosis;
Intrinsic factor antibody abnormal;
Intrinsic factor antibody positive;
IPEX syndrome;
Irregular breathing;
IRVAN syndrome;
IVth nerve paralysis;
IVth nerve paresis;
JC polyomavirus test positive;
JC virus CSF test positive;
Jeavons syndrome;
Jugular vein embolism;
Jugular vein thrombosis;
Juvenile idiopathic arthritis;
Juvenile myoclonic epilepsy;
Juvenile polymyositis;
Juvenile psoriatic arthritis;
Juvenile spondyloarthritis;
Kaposi sarcoma inflammatory cytokine syndrome;
Kawasaki's disease;
Kayser-Fleischer ring;
Keratoderma blenorrhagica;
Ketosis-prone diabetes mellitus;
Kounis syndrome;
Lafora's myoclonic epilepsy;
Lambl's excrescences;
Laryngeal dyspnoea;
Laryngeal oedema;
Laryngeal rheumatoid arthritis;
Laryngospasm;
Laryngotracheal oedema;
Latent autoimmune diabetes in adults;
LE cells present;
Lemierre syndrome;
Lennox-Gastaut syndrome;
Leucine aminopeptidase increased;
Leukoencephalomyelitis;
Leukoencephalopathy;
Leukopenia;
Leukopenia neonatal;
Lewis-Sumner syndrome;
Lhermitte's sign;
Lichen planopilaris;
Lichen planus;
Lichen sclerosus;
Limbic encephalitis;
Linear IgA disease;
Lip oedema;
Lip swelling;
Liver function test abnormal;
Liver function test decreased;
Liver function test increased;
Liver induration;
Liver injury;
Liver iron concentration abnormal;
Liver iron concentration increased;
Liver opacity;
Liver palpable;
Liver sarcoidosis;
Liver scan abnormal;
Liver tenderness;
Low birth weight baby;
Lower respiratory tract herpes infection;
Lower respiratory tract infection;
Lower respiratory tract infection viral;
Lung abscess;
Lupoid hepatic cirrhosis;
Lupus cystitis;
Lupus encephalitis;
Lupus endocarditis;
Lupus enteritis;
Lupus hepatitis;
Lupus myocarditis;
Lupus myositis;
Lupus nephritis;
Lupus pancreatitis;
Lupus pleurisy;
Lupus pneumonitis;
Lupus vasculitis;
Lupus-like syndrome;
Lymphocytic hypophysitis;
Lymphocytopenia neonatal;
Lymphopenia;
MAGIC syndrome;
Magnetic resonance imaging liver abnormal;
Magnetic resonance proton density fat fraction measurement;
Mahler sign;
Manufacturing laboratory analytical testing issue;
Manufacturing materials issue;
Manufacturing production issue;
Marburg's variant multiple sclerosis;
Marchiafava-Bignami disease;
Marine Lenhart syndrome;
Mastocytic enterocolitis;
Maternal exposure during pregnancy;
Medical device site thrombosis;
Medical device site vasculitis;
MELAS syndrome;
Meningitis;
Meningitis aseptic;
Meningitis herpes;
Meningoencephalitis herpes simplex neonatal;
Meningoencephalitis herpetic;
Meningomyelitis herpes;
MERS-CoV test;
MERS-CoV test negative;
MERS-CoV test positive;
Mesangioproliferative glomerulonephritis;
Mesenteric artery embolism;
Mesenteric artery thrombosis;
Mesenteric vein thrombosis;
Metapneumovirus infection;
Metastatic cutaneous Crohn's disease;
Metastatic pulmonary embolism;
Microangiopathy;
Microembolism;
Microscopic polyangiitis;
Middle East respiratory syndrome;
Migraine-triggered seizure;
Miliary pneumonia;
Miller Fisher syndrome;
Mitochondrial aspartate aminotransferase increased;
Mixed connective tissue disease;
Model for end stage liver disease score abnormal;
Model for end stage liver disease score increased;
Molar ratio of total branched-chain amino acid to tyrosine;
Molybdenum cofactor deficiency;
Monocytopenia;
Mononeuritis;
Mononeuropathy multiplex;
Morphoea;
Morvan syndrome;
Mouth swelling;
Moyamoya disease;
Multifocal motor neuropathy;
Multiple organ dysfunction syndrome;
Multiple sclerosis;
Multiple sclerosis relapse;
Multiple sclerosis relapse prophylaxis;
Multiple subpial transection;
Multisystem inflammatory syndrome in children;
Muscular sarcoidosis;
Myasthenia gravis;
Myasthenia gravis crisis;
Myasthenia gravis neonatal;
Myasthenic syndrome;
Myelitis;
Myelitis transverse;
Myocardial infarction;
Myocarditis;
Myocarditis post infection;
Myoclonic epilepsy;
Myoclonic epilepsy and ragged-red fibres;
Myokymia;
Myositis;
Narcolepsy;
Nasal herpes;
Nasal obstruction;
Necrotising herpetic retinopathy;
Neonatal Crohn's disease;
Neonatal epileptic seizure;
Neonatal lupus erythematosus;
Neonatal mucocutaneous herpes simplex;
Neonatal pneumonia;
Neonatal seizure;
Nephritis;
Nephrogenic systemic fibrosis;
Neuralgic amyotrophy;
Neuritis;
Neuritis cranial;
Neuromyelitis optica pseudorelapse;
Neuromyelitis optica spectrum disorder;
Neuromyotonia;
Neuronal neuropathy;
Neuropathy peripheral;
Neuropathy, ataxia, retinitis pigmentosa syndrome;
Neuropsychiatric lupus;
Neurosarcoidosis;
Neutropenia;
Neutropenia neonatal;
Neutropenic colitis;
Neutropenic infection;
Neutropenic sepsis;
Nodular rash;
Nodular vasculitis;
Noninfectious myelitis;
Noninfective encephalitis;
Noninfective encephalomyelitis;
Noninfective oophoritis;
Obstetrical pulmonary embolism;
Occupational exposure to communicable disease;
Occupational exposure to SARS-CoV-2;
Ocular hyperaemia;
Ocular myasthenia;
Ocular pemphigoid;
Ocular sarcoidosis;
Ocular vasculitis;
Oculofacial paralysis;
Oedema;
Oedema blister;
Oedema due to hepatic disease;
Oedema mouth;
Oesophageal achalasia;
Ophthalmic artery thrombosis;
Ophthalmic herpes simplex;
Ophthalmic herpes zoster;
Ophthalmic vein thrombosis;
Optic neuritis;
Optic neuropathy;
Optic perineuritis;
Oral herpes;
Oral lichen planus;
Oropharyngeal oedema;
Oropharyngeal spasm;
Oropharyngeal swelling;
Osmotic demyelination syndrome;
Ovarian vein thrombosis;
Overlap syndrome;
Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection;
Paget-Schroetter syndrome;
Palindromic rheumatism;
Palisaded neutrophilic granulomatous dermatitis;
Palmoplantar keratoderma;
Palpable purpura;
Pancreatitis;
Panencephalitis;
Papillophlebitis;
Paracancerous pneumonia;
Paradoxical embolism;
Parainfluenzae viral laryngotracheobronchitis;
Paraneoplastic dermatomyositis;
Paraneoplastic pemphigus;
Paraneoplastic thrombosis;
Paresis cranial nerve;
Parietal cell antibody positive;
Paroxysmal nocturnal haemoglobinuria;
Partial seizures;
Partial seizures with secondary generalisation;
Patient isolation;
Pelvic venous thrombosis;
Pemphigoid;
Pemphigus;
Penile vein thrombosis;
Pericarditis;
Pericarditis lupus;
Perihepatic discomfort;
Periorbital oedema;
Periorbital swelling;
Peripheral artery thrombosis;
Peripheral embolism;
Peripheral ischaemia;
Peripheral vein thrombus extension;
Periportal oedema;
Peritoneal fluid protein abnormal;
Peritoneal fluid protein decreased;
Peritoneal fluid protein increased;
Peritonitis lupus;
Pernicious anaemia;
Petit mal epilepsy;
Pharyngeal oedema;
Pharyngeal swelling;
Pityriasis lichenoides et varioliformis acuta;
Placenta praevia;
Pleuroparenchymal fibroelastosis;
Pneumobilia;
Pneumonia;
Pneumonia adenoviral;
Pneumonia cytomegaloviral;
Pneumonia herpes viral;
Pneumonia influenzal;
Pneumonia measles;
Pneumonia mycoplasmal;
Pneumonia necrotising;
Pneumonia parainfluenzae viral;
Pneumonia respiratory syncytial viral;
Pneumonia viral;
POEMS syndrome;
Polyarteritis nodosa;
Polyarthritis;
Polychondritis;
Polyglandular autoimmune syndrome type I;
Polyglandular autoimmune syndrome type II;
Polyglandular autoimmune syndrome type III;
Polyglandular disorder;
Polymicrogyria;
Polymyalgia rheumatica;
Polymyositis;
Polyneuropathy;
Polyneuropathy idiopathic progressive;
Portal pyaemia; Portal vein embolism;
Portal vein flow decreased;
Portal vein pressure increased;
Portal vein thrombosis;
Portosplenomesenteric venous thrombosis;
Post procedural hypotension;
Post procedural pneumonia;
Post procedural pulmonary embolism;
Post stroke epilepsy;
Post stroke seizure;
Post thrombotic retinopathy;
Post thrombotic syndrome;
Post viral fatigue syndrome;
Postictal headache;
Postictal paralysis;
Postictal psychosis;
Postictal state;
Postoperative respiratory distress;
Postoperative respiratory failure;
Postoperative thrombosis;
Postpartum thrombosis;
Postpartum venous thrombosis;
Postpericardiotomy syndrome;
Post-traumatic epilepsy;
Postural orthostatic tachycardia syndrome;
Precerebral artery thrombosis;
Pre-eclampsia;
Preictal state;
Premature labour;
Premature menopause;
Primary amyloidosis;
Primary biliary cholangitis;
Primary progressive multiple sclerosis;
Procedural shock;
Proctitis herpes;
Proctitis ulcerative;
Product availability issue;
Product distribution issue;
Product supply issue;
Progressive facial hemiatrophy;
Progressive multifocal leukoencephalopathy;
Progressive multiple sclerosis;
Progressive relapsing multiple sclerosis;
Prosthetic cardiac valve
thrombosis;
Pruritus;
Pruritus allergic;
Pseudovasculitis;
Psoriasis;
Psoriatic arthropathy;
Pulmonary amyloidosis;
Pulmonary artery thrombosis;
Pulmonary embolism;
Pulmonary fibrosis;
Pulmonary haemorrhage;
Pulmonary microemboli;
Pulmonary oil microembolism;
Pulmonary renal syndrome;
Pulmonary sarcoidosis;
Pulmonary sepsis;
Pulmonary thrombosis;
Pulmonary tumour thrombotic microangiopathy;
Pulmonary vasculitis;
Pulmonary veno-occlusive disease;
Pulmonary venous thrombosis;
Pyoderma gangrenosum;
Pyostomatitis vegetans;
Pyrexia; Quarantine;
Radiation leukopenia;
Radiculitis brachial;
Radiologically isolated syndrome;
Rash; Rash erythematous;
Rash pruritic;
Rasmussen encephalitis;
Raynaud's phenomenon;
Reactive capillary endothelial proliferation;
Relapsing multiple sclerosis;
Relapsing-remitting multiple sclerosis;
Renal amyloidosis;
Renal arteritis;
Renal artery thrombosis;
Renal embolism;
Renal failure;
Renal vascular thrombosis;
Renal vasculitis;
Renal vein embolism;
Renal vein thrombosis;
Respiratory arrest;
Respiratory disorder;
Respiratory distress;
Respiratory failure;
Respiratory paralysis;
Respiratory syncytial virus bronchiolitis
Retinal artery embolism;
Retinal artery occlusion;
Retinal artery thrombosis;
Retinal vascular thrombosis;
Retinal vasculitis;
Retinal vein occlusion;
Retinal vein thrombosis;
Retinol binding protein decreased;
Retinopathy;
Retrograde portal vein flow;
Retroperitoneal fibrosis;
Reversible airways obstruction;
Reynold's syndrome;
Rheumatic brain disease;
Rheumatic disorder;
Rheumatoid arthritis;
Rheumatoid factor increased;
Rheumatoid factor positive;
Rheumatoid factor quantitative increased;
Rheumatoid lung;
Rheumatoid neutrophilic dermatosis;
Rheumatoid nodule;
Rheumatoid nodule removal;
Rheumatoid scleritis;
Rheumatoid vasculitis;
Saccadic eye movement;
SAPHO syndrome;
Sarcoidosis;
SARS-CoV-1 test;
SARS-CoV-1 test negative;
SARS-CoV-1 test
positive;
SARS-CoV-2 antibody test;
SARS-CoV-2 antibody test negative;
SARS-CoV-2 antibody test positive;
SARS-CoV-2 carrier;
SARS-CoV-2 sepsis;
SARS-CoV-2 test;
SARS-CoV-2 test false negative;
SARS-CoV-2 test false positive;
SARS-CoV-2 test negative; SARS-
CoV-2 test positive;
SARS-CoV-2 viraemia;
Satoyoshi syndrome;
Schizencephaly;
Scleritis;
Sclerodactylia;
Scleroderma;
Scleroderma associated digital ulcer;
Scleroderma renal crisis;
Scleroderma-like reaction;
Secondary amyloidosis;
Secondary cerebellar degeneration;
Secondary progressive multiple sclerosis;
Segmented hyalinising vasculitis;
Seizure;
Seizure anoxic;
Seizure cluster;
Seizure like phenomena;
Seizure prophylaxis;
Sensation of foreign body;
Septic embolus;
Septic pulmonary embolism;
Severe acute respiratory syndrome;
Severe myoclonic epilepsy of infancy;
Shock;
Shock symptom;
Shrinking lung syndrome;
Shunt thrombosis;
Silent thyroiditis;
Simple partial seizures;
Sjogren's syndrome;
Skin swelling;
SLE arthritis;
Smooth muscle antibody positive;
Sneezing;
Spinal artery embolism;
Spinal artery thrombosis;
Splenic artery thrombosis;
Splenic embolism;
Splenic thrombosis;
Splenic vein thrombosis;
Spondylitis;
Spondyloarthropathy;
Spontaneous heparin-induced thrombocytopenia syndrome;
Status epilepticus;
Stevens-Johnson syndrome;
Stiff leg syndrome;
Stiff person syndrome;
Stillbirth;
Still's disease;
Stoma site thrombosis;
Stoma site vasculitis;
Stress cardiomyopathy;
Stridor;
Subacute cutaneous lupus erythematosus;
Subacute endocarditis;
Subacute inflammatory demyelinating polyneuropathy;
Subclavian artery embolism;
Subclavian artery thrombosis;
Subclavian vein thrombosis;
Sudden unexplained death in epilepsy;
Superior sagittal sinus thrombosis;
Susac's syndrome;
Suspected COVID-19;
Swelling;
Swelling face;
Swelling of eyelid;
Swollen tongue;
Sympathetic ophthalmia;
Systemic lupus erythematosus;
Systemic lupus erythematosus disease activity index abnormal;
Systemic lupus erythematosus disease activity index decreased; Systemic lupus erythematosus disease activity index increased;
Systemic lupus erythematosus rash;
Systemic scleroderma;
Systemic sclerosis pulmonary;
Tachycardia;
Tachypnoea;
Takayasu's arteritis;
Temporal lobe epilepsy;
Terminal ileitis;
Testicular autoimmunity;
Throat tightness;
Thromboangiitis obliterans;
Thrombocytopenia;
Thrombocytopenic purpura;
Thrombophlebitis;
Thrombophlebitis migrans;
Thrombophlebitis neonatal;
Thrombophlebitis septic;
Thrombophlebitis superficial;
Thromboplastin antibody positive;
Thrombosis;
Thrombosis corpora cavernosa;
Thrombosis in device;
Thrombosis mesenteric vessel;
Thrombotic cerebral infarction;
Thrombotic microangiopathy;
Thrombotic stroke;
Thrombotic thrombocytopenic purpura;
Thyroid disorder;
Thyroid stimulating immunoglobulin increased;
Thyroiditis; Tongue amyloidosis;
Tongue biting;
Tongue oedema;
Tonic clonic movements;
Tonic convulsion;
Tonic posturing;
Topectomy;
Total bile acids increased;
Toxic epidermal necrolysis;
Toxic leukoencephalopathy;
Toxic oil syndrome;
Tracheal obstruction;
Tracheal oedema;
Tracheobronchitis;
Tracheobronchitis mycoplasmal;
Tracheobronchitis viral;
Transaminases abnormal;
Transaminases increased;
Transfusion-related alloimmune neutropenia;
Transient epileptic amnesia;
Transverse sinus thrombosis;
Trigeminal nerve paresis;
Trigeminal neuralgia;
Trigeminal palsy;
Truncus coeliacus thrombosis;
Tuberous sclerosis complex;
Tubulointerstitial nephritis and uveitis syndrome;
Tumefactive multiple sclerosis;
Tumour embolism;
Tumour thrombosis;
Type 1 diabetes mellitus;
Type I hypersensitivity;
Type III immune complex mediated reaction;
Uhthoff's phenomenon;
Ulcerative keratitis;
Ultrasound liver abnormal;
Umbilical cord thrombosis;
Uncinate fits;
Undifferentiated connective tissue disease;
Upper airway obstruction;
Urine bilirubin increased;
Urobilinogen urine decreased;
Urobilinogen urine
increased;
Urticaria;
Urticaria papular;
Urticarial vasculitis;
Uterine rupture;
Uveitis;
Vaccination site thrombosis;
Vaccination site vasculitis;
Vagus nerve paralysis;
Varicella;
Varicella keratitis;
Varicella post vaccine;
Varicella zoster gastritis;
Varicella zoster oesophagitis;
Varicella zoster pneumonia;
Varicella zoster sepsis;
Varicella zoster virus infection;
Vasa praevia;
ascular graft thrombosis;
Vascular pseudoaneurysm thrombosis;
Vascular purpura;
Vascular stent thrombosis;
Vasculitic rash;
Vasculitic ulcer;
Vasculitis;
Vasculitis gastrointestinal;
Vasculitis necrotising;
Vena cava embolism;
Vena cava thrombosis;
Venous intravasation;
Venous recanalisation;
Venous thrombosis;
Venous thrombosis in pregnancy;
Venous thrombosis limb;
Venous thrombosis neonatal;
Vertebral artery thrombosis;
Vessel puncture site thrombosis;
Visceral venous thrombosis;
VIth nerve paralysis;
VIth nerve paresis;
Vitiligo;
Vocal cord paralysis;
Vocal cord paresis;
Vogt-Koyanagi-Harada disease;
Warm type haemolytic anaemia;
Wheezing;
White nipple sign;
XIth nerve paralysis;
X-ray hepatobiliary abnormal;
Young's syndrome;
Zika virus associated Guillain Barre syndrome.

https://x22report.com/aiovg_videos/d...-the-death-jab

1:20:01 video runtime

Dr. Zelenko – The [DS] Did Not Reach Their Goal, There Is Hope For Those Who Received The Death Jab
SPREAD THE WORD

Z Stack Life -> http://zstacklife.com/x22

Today’s Guest: Dr. Zelenko

Dr. Zelenko Board Certified Family Physician with over 20 years experience. Dr. Zelenko was nominated for the Presidential Medal of Freedom and the Nobel Prize , Dr. Zelenko’s team was one of the first in the country to successfully treat thousands of Covid-19 patients in the prehospital setting. Dr. Zelenko developed his now famous “Zelenko Protocol,” which has saved countless lives worldwide. Dr. Zelenko recommended that President Trump take hydroxychloroquine. Dr. Zelenko begins the conversation explaining that the death jab will have medical problems because the death jab was not a vaccine, it was to reduce the population and the [DS]/Big Pharma fell short of their goal. But there is hope, those who received the death jab have the ability to shield or maybe even reverse what was given to them.

https://childrenshealthdefense.salsalabs.org/3-6-22defenderweekly?wvpId=a64cbeac-eb3d-41f6-974e-52f8708741e3


Go to the link above for a hyperlinked list of Children's Health Defense top stories of the week .

March 6, 2022

MOST READ NEWS OF the week

Pfizer Vaccine Only 12% Effective in Kids 5 to 11, Study Says

Woman Died of Blood Disorder After J&J Vaccine. CDC Says the Disorder Is Rare — But Is It?

NY Times Ran Another Hit Piece on RFK, Jr. It's Time to Hit Back.

Biden’s ‘Test to Treat’ Plan a Windfall for Pfizer, Merck — But Bad for Patients, Doctors Say

Saturday Night Live Takes on (Gasp!) Masks and Vaccines

Backed by Big Pharma, NewsGuard Brings ‘Fact Checking’ to Tens of Millions of Kids in Schools

I’m a Progressive Democrat. Here’s Why I Felt Impelled to Review RFK, Jr.’s ‘The Real Anthony Fauci.’

Internal Memo Shows Biden, CDC Following Poll Numbers, Not Science

Booster Shots Causing More Injuries Than Previously Thought, Israeli Survey Shows

RFK, Jr. Interviews Vanden Bossche: Why Vaccinating for Omicron Could Make Pandemic More Deadly

https://beckernews.com/the-u-s-gover...hNotifications


The U.S. Government Paid Media Outlets Millions of Dollars While They Ran Covid-19 Vaccine Propaganda
March 6, 2022
by Kyle Becker

embedded taxpayer funded video featuring Whoopi Goldberg and other propagandists and crisis actors.

The U.S. government ran a ‘comprehensive’ media relations program that paid millions of dollars to media outlets to influence the American public to be ‘pro-vaccine.’ This program included purchasing advertising from some of the biggest TV and digital media outlets, which subsequently failed in almost every instance to report the conflict of interest, accompanied by near-uniformly positive and uncritical Covid vaccine reportage.

The government documents describing the media relations program were reported by The Blaze in an “exclusive.”

“In response to a FOIA request filed by TheBlaze, HHS revealed that it purchased advertising from major news networks including ABC, CBS, and NBC, as well as cable TV news stations Fox News, CNN, and MSNBC, legacy media publications including the New York Post, the Los Angeles Times, and the Washington Post, digital media companies like BuzzFeed News and Newsmax, and hundreds of local newspapers and TV stations,” The Blaze’s story notes. “These outlets were collectively responsible for publishing countless articles and video segments regarding the vaccine that were nearly uniformly positive about the vaccine in terms of both its efficacy and safety.”

“Hundreds of news organizations were paid by the federal government to advertise for the vaccines as part of a ‘comprehensive media campaign,'” according to documents TheBlaze obtained from the Department of Health and Human Services. “The Biden administration purchased ads on TV, radio, in print, and on social media to build vaccine confidence, timing this effort with the increasing availability of the vaccines. The government also relied on earned media featuring “influencers” from ‘communities hit hard by COVID-19’ and ‘experts’ like White House chief medical adviser Dr. Anthony Fauci and other academics to be interviewed and promote vaccination in the news.”

“Though virtually all of these newsrooms produced stories covering the COVID-19 vaccines, the taxpayer dollars flowing to their companies were not disclosed to audiences in news reports, since common practice dictates that editorial teams operate independently of media advertising departments and news teams felt no need to make the disclosure,” as some publications The Blaze reached for comment explained.

“The Biden administration engaged in a massive campaign to educate the public and promote vaccination as the best way to prevent serious illness or death from COVID-19,” the story notes. “Congress appropriated $1 billion in fiscal year 2021 for the secretary of health to spend on activities to ‘strengthen vaccine confidence in the United States.’ Federal law authorizes HHS to act through the U.S. Centers for Disease Control and Prevention and other agencies to award contracts to public and private entities to ‘carry out a national, evidence-based campaign to increase awareness and knowledge of the safety and effectiveness of vaccines for the prevention and control of diseases, combat misinformation about vaccines, and disseminate scientific and evidence-based vaccine-related information, with the goal of increasing rates of vaccination across all ages … to reduce and eliminate vaccine-preventable diseases’.”

The story notes a good example of product placement. “Fear-based vaccine ads” from HHS featuring “survivor” stories from Covid patients in ICUs were covered on CNN and discussed on ABC’s “The View” after they were released. Watch:

embedded video

7:25 video runtime

video also viewable on Rumble

https://rumble.com/vwm5ib-the-view-does-pr-for-covid-vaccine-boosters.html

In the absence of liability for pharmaceutical companies or the ability to hold them accountable for false or misleading claims, the mass promotion of ‘vaccines’ that were rushed to market after a bare modicum of testing constitutes the most egregious breach of journalistic ethics. There was a complete lack of transparency from the pharmaceutical compannies, the Food and Drug Administration, and the media outlets that promoted these vaccines.

Compounding this unethical journalistic behavior, Big Tech companies and self-appointed ‘watchdogs’ maintained relationships that constituted conflicts of interest, including partnerships with pharmaceutical companies and the U.S. government. Newsguard, for example, partners with the U.S. Department of Defense and the U.S. State Department, but polices the Internet for examples of what its editors consider to be “misinformation.” This attempt to ‘chill speech’ ostensibly represents a violation of Americans’ First Amendment rights, because the U.S. government is forbidden from infringing on free speech — even through third parties.

Facebook partnered with the CDC for a massive Covid vaccine propaganda push that included censorship against those who were ‘vaccine hesitant’ because they demanded evidence for their efficacy and for such claims as they ‘stop the spread.’ Twitter also banned and deplatformed critics such as Alex Berenson, even when they later quietly conceded that the critics had been right.

The Covid-19 vaccine rollout thus compromises one of the most deceptive propaganda campaigns in U.S. history. If the American people do not push for accountability for this monumental effort to manipulate the public, then it will only get worse.

The floodgates have been opened. Voters need to decide if they want a U.S. government that spends billions in taxpayer funds every year to engage in propaganda. This time it was to push pharmaceutical products. Next time, it may be much worse.

https://static-3.bitchute.com/live/c...Jx_320x180.jpg
Edward Dowd interviewed by Naomi Wolf

"The data is fraud. The whole thing is a fraud."
Edward Dowd

https://www.bitchute.com/video/CuUvdDw3luJx/

1:01:14 video runtime

BOMBSHELL! Edward Dowd Interviewed by Naomi Wolf on Covid Crime Against Humanity

First published at 15:42 UTC on March 6th, 2022.

channel image

Jim Fetzer

Jim Fetzer

9863 subscribers

REQUIRED VIEWING! This is former BlackRock Portfolio Manager, Edward Dowd, telling SERIOUS TRUTH about the fraudulent imposition of the Covid-19 pandemic on the people of the world. Interviewed by Naomi Wolf from March 1, 2022.

https://www.youtube.com/watch?v=dxNGASH9rUM

https://www.youtube.com/watch?v=dxNGASH9rUM

Life Insurance Companies Warn All Cause Deaths SPIKED In 2021

13:28 video runtime

Mar 2, 2022

Kim Iversen

342K subscribers

Depending on what the data shows that is now being released by the CDC, the life insurance companies may end up battling it out in court. 10,000 pages of the vaccine trials data was released a few days ago.

Moderna company is going to fail. Pfizer is going to be seriously wounded with stock price going down to, I believe Dowd said, "double digits", but after a long time in the ditch, it will eventually survive. Sounds like CDC, FDA, and NIH are in serious trouble for fraud that has killed hundreds of thousands of people all over the world..

Kim Iverson is a good reporter on her ow You Tube channel.

Rough road ahead for USA economy.